-
Finding a 'needle' in a 'haystack' just got easier
03/13/2019
Software helps to reduce error rates in next-generation sequencing data, expanding the clinical potential for the information.
-
How one patient revealed a new route to melanoma
03/04/2019
Read latest on a mutation that drives the most common childhood melanoma plus evidence that patients who carry the alteration may respond to precision medicine.
-
Radiation triples survival for a rare brain tumor
03/01/2019
Treatment success shown in ependymoma clinic trial open at more than 100 locations and with nearly 400 patients.
-
Unraveling the connection between ancestry and cancer
02/21/2019
Scientists found variations in a fourth gene that is linked to a 50% increased ALL risk in Hispanic children. The risk was much lower for non-Hispanic children with the variation.
-
Reducing alert fatigue
02/13/2019
A time-consuming issue for clinicians is assessing drug alerts in EHR systems. Researchers evaluated alerts and found ways to safely reduce alert overrides by 40 percent.
-
Reprogramming immune cells to fight tumors from within
10/19/2018
Scientists have a new strategy to enhance the anti-cancer immune response and slow tumor growth. The goal is to reprogram macrophages to eliminate tumor cells.
-
Rhabdomyosarcoma discoveries move from lab to clinic
08/23/2018
St. Jude scientists have completed the most complete analysis yet of the muscle and soft tissue tumor rhabdomyosarcoma.
-
NCI awards ‘exceptional’ rating to St. Jude Comprehensive Cancer Center
08/22/2018
For the second time in a row, the National Cancer Institute (NCI) has awarded St. Jude the highest possible rank of “exceptional” during renewal of the hospital’s Comprehensive Cancer Center grant.
-
Discovery may help some children avoid bone marrow transplantation
07/26/2018
Researchers have solved a decades-old mystery about which mutations cause a rare, inherited bone marrow disorder. The answer may allow some children to avoid bone marrow transplantation.
-
St. Jude partners with University of Washington to improve knowledge worldwide
07/18/2018
St. Jude and the Institute for Health Metrics and Evaluation at the University of Washington are partnering to advance knowledge and understanding of childhood cancer around the world.
-
Scientists identify a protein complex that shapes T cells’ destiny
07/06/2018
Like a mentor helping medical students choose between specialties, a protein complex helps shape the destiny of developing T cells, according to St. Jude scientists.
-
Genetic counseling suggested for all childhood cancer survivors
06/19/2018
St. Jude has completed the first genome sequencing of cancer survivors and found that 12 percent of childhood cancer survivors may have a higher risk of cancer.
-
Brain tumor subtype discovered that responds to less-aggressive treatment
05/17/2018
St. Jude researchers have discovered that a quarter of medulloblastoma patients have the infant SHH-II subtype. These patients may respond to less aggressive forms of chemotherapy, sparing them a lifetime of side-effects from treatment.
-
WHO expands partnership with St. Jude
05/16/2018
St. Jude is the first WHO Collaborating Centre for Childhood Cancer. Read more about our exciting efforts to increase survival rates of children with pediatric cancer worldwide.
-
A protein ‘gone rogue’ may lead to new cancer treatments
05/16/2018
A protein has been identified that may help researchers target and kill cancer cells more effectively. Learn more about this exciting discovery.
-
Research pinpoints crucial flu mutation
04/24/2018
A mutation has been identified that may help scientists determine how to manufacture drugs to better fight the influenza virus. Learn more about the advances of treating drug resistant viruses.
-
Fourth ALL predisposition gene discovered
04/19/2018
Scientists have discovered a new gene mutation that may help predetermine a child’s risk for developing ALL. Explore the latest breakthroughs.
-
Injured cells and genetic variation may highlight a risk of neurocognitive problems
03/29/2018
St. Jude researchers recently discovered neurocognitive side-effects in patients may stem from leukemia itself, rather than solely from treatment-related causes. Read the latest.
-
Molecule identified that serves as a sentinel for the immune system
03/22/2018
One specific molecule might be the key to preventing infections in pediatric patients. Learn more about this new discovery.
-
How socially connected are cancer survivors? The answer might surprise you.
03/08/2018
As cancer survivorship increases, so do efforts to understand and strengthen social support and advice. Read the latest.
-
A new avenue to prevent hearing loss
03/07/2018
The chemotherapy drug cisplatin may help save a child’s life. But that same medication can also damage a child’s hearing.
-
At the deepest level, children are not just small adults when it comes to cancer
02/28/2018
A comprehensive analysis of the genes and mutations driving childhood cancer reveals just how different the disease is in children and adults.
-
St. Jude Announces Plans for State-of-the-Art Advanced Research Center
02/19/2018
St. Jude announces plans for a new, state-of-the-art advanced research center that will reinforce the scientific efforts of our faculty members. Learn more about this new addition to the St. Jude community.
-
Bringing hope and effective treatment to young refugees with cancer
02/18/2018
The Lebanese refugee crisis offers lessons in how to provide effective treatment for cancer and chronic diseases during emergencies.
-
The chance to earn modest rewards may help get kids moving
02/12/2018
Want young cancer survivors to stay active? Pilot study finds the chance to earn stickers, T-shirts and other rewards helps keep survivors moving.
-
DNA in 3-D reveals a ‘hijacking’ that drives neuroblastoma
01/23/2018
The oncogene c-MYC drives high-risk neuroblastoma in some young cancer patients. The findings lay the groundwork for much needed precision medicines.
-
Improving vaccination rates in hospitals
01/10/2018
A St. Jude quality improvement initiative that greatly increased the employee vaccination rate for pertussis, or whooping cough, offers a model for other health care institutions nationwide.
-
A double whammy for leukemia patients
01/04/2018
St. Jude scientists have discovered new germline variations in a tumor suppressor gene called TP53. Children with these variants are at risk of developing leukemia.
